作者
Bailey Gleason Fitzgerald, Thomas Urban Marron, Nicole Hall, Daniel O'Grady, Nelson LaMarche, Clotilde Hennequin, Samarth Hegde, Barbara Maier, Jessica Le Berichel, Udit Chadda, Mary Beth Beasley, David F Yankelevitz, Jorge E Gomez, Deborah Blythe Doroshow, Rajwanth Veluswamy, Nicholas Cole Rohs, Christian Diego Rolfo, Fred R Hirsch, Miriam Merad
发表日期
2022/6/1
来源
Journal of Clinical Oncology
卷号
40
期号
16_suppl
页码范围
TPS9139-TPS9139
出版商
American Society of Clinical Oncology
简介
TPS9139
Background: Although tumor microenvironments may contain chronic inflammatory cells, this milieu can lead to immune evasion and may contribute to resistance to immunotherapy. Dendritic cells are one of the most potent cross presenters of tumor antigen, and their function is crucial to tumor-directed adaptive immune responses. In the KP mouse model of lung adenocarcinoma (KrasG12D; Tp53-/-), we recently identified interleukin-4 (IL-4)-driven suppression of tumor-antigen charged dendritic cells, which was similarly seen in human lung cancer lesions (Maier, B., et al., A conserved dendritic-cell regulatory program limits antitumour immunity. Nature, 2020.580[7802]:257-262). In the mouse model IL-4 blockade resulted in an increase in IL-12, IFNg and TNF in CD8+ T cells and decreased tumor burden, and further antitumor activity was seen when combined with PD-L1 blockade. Dupilumab is a fully …
学术搜索中的文章
BG Fitzgerald, TU Marron, N Hall, D O'Grady… - 2022